Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for failing to disclose material information, leading to significant financial losses for investors during the class period from May 1, 2024, to May 7, 2025 [1][3]. Group 1: Lawsuit Details - Investors who purchased securities of Compass during the class period have until July 8, 2025, to file lead plaintiff applications [1][2]. - The lawsuit alleges that Compass and certain executives violated federal securities laws by not disclosing critical information [3]. - Following the announcement of an internal investigation and the need to restate financial statements for fiscal 2024, Compass's share price dropped approximately 62%, from $17.25 on May 7, 2025, to $6.55 on May 8, 2025 [4]. Group 2: Company Background - Compass Diversified Holdings is currently under scrutiny due to irregularities identified in its subsidiary, Lugano Holding, Inc., related to financing, accounting, and inventory practices [4]. - The Audit Committee of Compass's Board has initiated an investigation after concerns were raised about Lugano's financial practices [4]. - Kahn Swick & Foti, LLC, the law firm handling the case, is recognized as one of the top securities litigation firms in the nation, serving various clients seeking recoveries for investment losses [5].

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Compass Diversified Holdings (“CODI” or the “Company”) (NYSE: CODI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether CODI and certain of it ...

Core Insights - The article expresses cautious optimism regarding Compass Therapeutics (NASDAQ: CMPX) and highlights the importance of an upcoming readout that is expected to occur early in the year [1]. Company Analysis - Compass Therapeutics is under scrutiny for its clinical trials and the potential implications of the results on its stock performance [1]. - The author has a background in biochemistry and extensive experience in analyzing biotech companies, which adds credibility to the insights shared about Compass Therapeutics [1]. Industry Context - The article emphasizes the significance of understanding the science behind biotech investments, suggesting that investors should conduct thorough due diligence to avoid pitfalls in this sector [1].

Core Viewpoint - A class action lawsuit has been filed against Compass Diversified for allegedly making false and misleading statements regarding its financial practices and internal controls during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Central District of California on behalf of all individuals and entities who purchased Compass securities between May 1, 2024, and May 7, 2025 [1]. - Investors have until July 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against the Company - The lawsuit claims that Compass's subsidiary, Lugano Holdings, Inc., had unrecorded financing arrangements and irregularities in its sales, cost of sales, inventory, and accounts receivable [3]. - It is alleged that these irregularities rendered the financial statements of Compass unreliable and would necessitate a restatement [3]. - The company is accused of failing to maintain adequate internal controls related to its financial statements, leading to materially false and misleading public statements [3].

Core Viewpoint - Compass Diversified (CODI) is under investigation for potential securities fraud and unlawful business practices following the disclosure of irregularities in its subsidiary, Lugano Holding, Inc. [1][2] Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of CODI regarding possible securities fraud or unlawful business practices [1] - On May 7, 2025, CODI announced a non-reliance on its financial statements for fiscal 2024 due to an ongoing internal investigation into Lugano Holding [2] - The Audit Committee of CODI's Board of Directors initiated an investigation after concerns were raised about Lugano's inventory financing practices, which identified irregularities in non-CODI financing, accounting, and inventory practices [2] Group 2: Financial Impact - Following the announcement of the investigation, CODI's stock price dropped by $10.70 per share, representing a decline of 62.03%, closing at $6.55 per share on May 8, 2025 [2]

Core Viewpoint - A class action lawsuit has been filed against Compass Group Diversified Holdings LLC due to alleged failures in financial reporting and internal controls, leading to significant stock price decline following the revelation of these issues [1][3][4]. Company Summary - The lawsuit, Nicholas Moreno v. Compass Group Diversified Holdings LLC, was initiated for investors who acquired securities between May 1, 2024, and May 7, 2025 [1]. - Allegations include the company's lack of effective internal controls over financial reporting and failure to disclose critical information regarding its subsidiary, Lugano Holding, Inc., which had undisclosed financing arrangements and irregularities in financial metrics [3]. - On May 7, 2025, Compass announced that its fiscal 2024 financial statements could no longer be relied upon due to an internal investigation into Lugano, leading to the resignation of Lugano's CEO without severance [4]. Market Impact - Following the announcement of the investigation, Compass' stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025, indicating a dramatic loss in market value [5].

Take advantage of the currently offered discount on annual memberships and give CIP a try. The offer comes with a 11 month money guarantee , for first time members.Conservative Income Portfolio targets the best value stocks with the highest margins of safety. The volatility of these investments is further lowered using the best priced options. Our Enhanced Equity Income Solutions Portfolio is designed to reduce volatility while generating 7-9% yields.We have not written about Compass Diversified (NYSE: CODI ...

Core Points - A class action has been filed against Compass Group Diversified Holdings, LLC (NYSE: CODI) on behalf of investors who acquired its securities between May 1, 2024, and May 7, 2025 [1] - The allegations include insufficient disclosure controls and failure to disclose unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable related to its subsidiary, Lugano Holdings, Inc. [2] - On May 7, 2025, Compass announced the need to restate its financial statements for fiscal 2024 due to identified irregularities in Lugano's financing and accounting practices, leading to a significant drop in stock price [3] Company Information - Compass Group Diversified Holdings, LLC is a statutory trust that manages a portfolio of small and middle-market businesses, including Lugano Holdings, Inc., which specializes in high-end jewelry [1] - The company is currently under investigation for its financial disclosures and practices related to its subsidiary [2][3] Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 8, 2025, to serve as lead plaintiff [4] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Compass Diversified due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by July 8, 2025 [4][6]. Group 1: Allegations Against Compass Diversified - The complaint alleges that Compass and its executives made false and misleading statements and failed to disclose irregularities in its subsidiary, Lugano Holdings, Inc., including unrecorded financing arrangements and issues with sales, cost of sales, inventory, and accounts receivable [6]. - It is claimed that the irregularities in Lugano's financial statements rendered Compass's overall financial statements unreliable and necessitated a restatement [6]. - The company is accused of failing to maintain adequate internal controls related to its financial statements, leading to materially false and misleading public statements [6]. Group 2: Impact on Stock and Investor Losses - On May 7, 2025, Compass disclosed that its financial statements for fiscal year 2024 should no longer be relied upon due to an ongoing internal investigation into Lugano Holdings, resulting in the resignation of Lugano's founder and CEO without severance [7]. - Following this disclosure, Compass Diversified's stock price fell by 8% during after-hours trading, causing significant losses for investors [8]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 in Compass stock or options between May 1, 2024, and May 7, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who can direct and oversee the litigation on behalf of the class [9]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Compass's conduct [10].

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Diversified (“CODI” or the “Company”) (NYSE: CODI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CODI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 7, 2025, CODI i ...